TELA Bio
TELA
49 hedge funds and large institutions have $200M invested in TELA Bio in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
71% more capital invested
Capital invested by funds: $117M → $200M (+$83.2M)
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
9% more funds holding
Funds holding: 45 → 49 (+4)
3.36% more ownership
Funds ownership: 87.61% → 90.97% (+3.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.54M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.34M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$660K |
| 4 |
Millennium Management
New York
|
+$485K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$325K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1M |
| 2 |
Calamos Advisors
Naperville,
Illinois
|
-$365K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$356K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$222K |
| 5 |
HF
HRT Financial
New York
|
-$117K |
TELA Hedge Fund Activity: Q4 2022 in Review
49 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in TELA Bio (TELA) for Q4 2022, worth a combined $200M — up 71% from $117M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TELA positions and 3 closed out — a net gain of 4 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.54M. The largest seller was Granite Point Capital Management, cutting an estimated $1M.
- 49 institutional investors held TELA Bio (TELA) as of Q4 2022, up from 45 in Q3 2022.
- Funds reported $200M of TELA Bio stock for Q4 2022, up 71% quarter-over-quarter.
- 7 funds opened new TELA Bio positions in Q4 2022 and 3 closed out, a net change of +4 holders.
- The largest TELA Bio buyer in Q4 2022 was Vanguard Group, an estimated $2.54M added.
- The largest TELA Bio seller in Q4 2022 was Granite Point Capital Management, an estimated $1M sold.
Based on aggregated 13F filings for Q4 2022.